Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1.9% in premarket trading after RBC Capital downgraded the stock to "Sector Perform" from "Outperform" and lowered its price target to $19 from $23.
RBC stated that the downgrade was primarily based on valuation considerations, as Biohaven's stock had risen approximately 100% from its 2026 lows and about 39% year-to-date, making the risk-reward profile less favorable.
RBC Downgrades Biohaven to "Sector Perform," Lowers Price Target to $19; Biohaven Shares Down 1.9% in Pre-market Trading
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
AIC Project and VELO Protocol: Technical Analysis, Market Status, and Derivatives Opportunities
-
2
POG Token: Project Overview, Market Status, and Trading Channel Analysis
-
3
WELUPS Coin: Investment Considerations Amidst Low Liquidity and Zero Circulating Supply
-
4
Ethereum 2.0 Terminology Deprecated: A Look Back at Major Ethereum Upgrades and Future Roadmap
-
5
KKC Coin: A Multifaceted Analysis – The Current State of Homonymous Tokens Like Kabberry Coin and Knoknok
-
6
Houthi attacks on multiple Saudi energy facilities disrupt operations, Brent crude rises 1.65% intraday, nearing $100 mark.
-
7
Binance Founder Changpeng Zhao (CZ): Still hiring humans.
-
8
Saudi Arabia announced that attacks have caused several energy facilities in its southern region to cease operations.
-
9
Brent crude oil climbs toward $100 as the Strait of Hormuz remains constrained
-
10
China's integrated circuit exports surged by 129.83% year-on-year in August, while crude oil imports increased by 6.2% month-on-month.
Markets Today
Recommended Reading







